MIRM Q1 2022 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M

Gross Profit

$10M81.2% margin

Operating Income

-$33M-253.9% margin

Net Income

-$37M-283.9% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

+310.8%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$278M

Total Liabilities

$169M

Stockholders' Equity

$109M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$0	—
Gross Profit	$10M	$0	—
Operating Income	-$33M	-$48M	+31.2%
Net Income	-$37M	-$51M	+27.6%

Revenue Segments

Product

$11M84%

License

$2M16%